Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Catalyst Pharmaceuticals Inc CPRX

Healthcare Biotechnology
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for... see more

Recent & Breaking News (NDAQ:CPRX)

Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2020

GlobeNewswire February 27, 2020

Catalyst Pharmaceuticals to Present at the Cowen 40th Annual Health Care Conference

GlobeNewswire February 26, 2020

Catalyst Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference

GlobeNewswire February 6, 2020

Catalyst Pharmaceuticals Appoints David Ailinger as Vice President, Business Development

GlobeNewswire February 4, 2020

Catalyst Pharmaceuticals Pre-Announces Estimated Firdapse® Revenues and Provides Updates on Advancement of Clinical Development Programs

GlobeNewswire January 6, 2020

Catalyst Pharmaceuticals to Participate in the Piper Jaffray 31st Annual Healthcare Conference

GlobeNewswire November 26, 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX

ACCESSWIRE IA November 16, 2019

Catalyst Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire November 12, 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX

GlobeNewswire November 11, 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX

ACCESSWIRE IA November 7, 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX

GlobeNewswire November 1, 2019

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Catalyst Pharmaceuticals, Inc. (CPRX)

ACCESSWIRE IA October 31, 2019

Catalyst Pharmaceuticals to Hold Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, November 13th, 2019

GlobeNewswire October 31, 2019

Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse® (Amifampridine Phosphate) in Patients with Congenital Myasthenic Syndromes (CMS)

GlobeNewswire October 30, 2019

Catalyst Pharmaceuticals to Participate in the 2019 Cantor Global Healthcare Conference

GlobeNewswire September 25, 2019

Catalyst Pharmaceuticals, Inc. Comments on Trading in its Common Stock and on its Capital Resources

GlobeNewswire September 23, 2019

Catalyst Pharmaceuticals, Inc. Determines Not to Proceed with Previously Announced Public Offering of Common Stock

GlobeNewswire September 13, 2019

Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

GlobeNewswire September 11, 2019

Catalyst Pharmaceuticals to Participate in the 14th Annual Citi Biotech Conference on September 4th, 2019

GlobeNewswire August 28, 2019

Catalyst Pharmaceuticals Announces Second Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire August 7, 2019